"In the setting of HIV/AIDS, leronlimab belongs to

"In the setting of HIV/AIDS, leronlimab belongs to a new class of therapeutics called viral-entry inhibitors; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. At the same time, leronlimab does not appear to interfere with the normal function of CCR5 in mediating immune responses. Leronlimab has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. Leronlimab has been designated a “fast track” product by the FDA. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use."
Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks https://seekingalpha.com/pr/17417467?source=ansh $CYDY

This is always present in every announcement published by CYDY. But since February 20, the following sentence has been deleted:

"At the same time, leronlimab does not appear to interfere with the normal function of CCR5 in mediating immune responses."